Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. - Wikidata - thesis-toulmin - TriplyDB

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.

http://www.wikidata.org/entity/Q41789122

about

Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K→︀AKT→︀GSK3β→︀AM signaling.PD-L1 expression in papillary renal cell carcinoma PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis.Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics.Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.Recent advances in renal cell carcinoma from a pathological point of view.Strategies to overcome therapeutic resistance in renal cell carcinoma.Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report.Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?Tumor-independent host secretomes induced by angiogenesis and immune-checkpoint inhibitors.Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies.The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in Kidney Cancer.

P2860

Q33721231-08BDD0FC-1FDE-421E-AD71-7AFCE7971265 Q36249417-6B6B92E2-C644-4901-A3AC-E61CE3359B5F Q37179971-FE36FD36-DE82-4984-B157-48D2E5158682 Q37392642-EA119750-24EB-41E5-9125-409CB0DAF2A0 Q37474651-56416853-8E81-4412-BA35-10778363456C Q38657787-FB41FF7A-0728-47D5-B8DE-6A08C71FA6F8 Q38707904-8448DF9B-C8D0-4483-BD0C-8DB3D4E71747 Q38720430-CE0ED746-44AE-4DD4-A73C-B09C4227F394 Q38742200-8C47E53A-9B0D-4A41-88B6-1D6FE0E1883C Q38909760-AFC457D4-5AF7-4390-A411-8AF7C31C46CB Q39089402-19989046-B071-4915-B19F-02991849C598 Q39210287-0A84234E-D7E3-41A9-9A48-04D0E4ECC06B Q39236837-2107FE5F-B2B8-498D-A9AD-1572056D1252 Q39406918-6A4FE004-0163-48FC-84AB-285D09259AF3 Q41369903-B3303239-F895-4453-AF17-42098B255828 Q42070314-B3E207F5-740A-4A9E-8B7E-7497696E05E2 Q47136084-64C4361F-E289-44BC-9F5E-EA2C99E66139 Q52562886-D138A825-F895-4C71-815F-A2DBB5445E8D Q52579594-FFADBF2E-1EF2-497C-92D8-86EE263BE85E Q53743967-4F432DE1-219B-4488-A392-063ED3C27406 Q55024837-2D100D2D-1E34-4FC2-A516-AA8278B1E337

P2860

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.

http://www.wikidata.org/entity/Q41789122

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Resistance to Antiangiogenic T ...... tastatic Renal Cell Carcinoma.

@en

type

label

Resistance to Antiangiogenic T ...... tastatic Renal Cell Carcinoma.

@en

prefLabel

Resistance to Antiangiogenic T ...... tastatic Renal Cell Carcinoma.

@en

P1433

Q41789122-FA77473D-E91A-4823-8DFC-D4B380756346

P1476

Q41789122-DB22148C-8979-4E67-8A90-411808CFE45F

P2093

Q41789122-14D193E9-A57F-411E-AE06-1B05C74607C5

Q41789122-1725FC05-4CDB-4A9E-9FF8-56D1BF6AA460

Q41789122-1BE2ECDE-9E8D-4165-AFCB-900AFF265515

Q41789122-32D12476-1451-4F20-AD80-924CED52F2D0

Q41789122-3BFA4FDA-487B-4AB6-AFA2-C65A1CCB4253

Q41789122-5435879C-307F-402F-8A88-C0AF6ADA6493

Q41789122-63E360B7-8546-4992-B502-FDEED13981AB

Q41789122-67DA3D39-6AE5-4DBE-8E96-6D858553A2B7

Q41789122-6EDB92CE-AE13-47D7-8827-2882BFB92EB6

Q41789122-73D868BC-AF9F-47E7-9884-D8705C16FEE1

P2860

Q41789122-14E17B7A-A59F-4C54-933F-2A0B343854F2

Q41789122-186C2BD3-F7DE-4536-B52A-623BE7FB3E85

Q41789122-18E2EC69-A2E0-4B7D-9BD8-A1149D4D463B

Q41789122-19230CED-D6ED-468A-8BF5-D19DB430A043

Q41789122-1ED7B514-DAE5-4209-9012-A024712B45B0

Q41789122-2DF389AF-8C4B-45A4-A7D0-62EB6B0A6009

Q41789122-312E547E-6D5B-4E2C-AB96-D3B6621E4E9B

Q41789122-3BB01E29-3B90-483F-B41A-E6F5D98B5EBC

Q41789122-3EAA9F00-11FB-4B90-9444-5C0B711131AD

Q41789122-47034085-EA01-4B3A-B5BA-9A50CE025815

P304

Q41789122-9246CDAF-3FB7-4A97-8631-AD9EE4CDC052

P31

Q41789122-9E81CE85-EEF2-496D-A6A5-F29E837A8FFA

P356

Q41789122-BB8E361F-50EE-4573-B120-3A67A3EF1076

P433

Q41789122-1D63DC50-33B6-4481-8820-D038DE3EAC94

P478

Q41789122-10C6D234-61D6-467A-A911-28C26A19E792

P50

Q41789122-FE962C99-7CEE-4F15-9761-F8FC1B1A757E

P577

Q41789122-15D83D9A-3311-4B54-A59A-C7A7382FE6B3

P5875

Q41789122-B4FD6D0E-C3F8-4E5B-9240-1445BF8E8F5C

P698

Q41789122-A60B22C1-4308-4826-A0DB-81292A1CC281

P932

Q41789122-936F11FD-4595-4F72-8EAD-EF68EAA9F31D

P356

2326-6066.CIR-14-0244

P1433

Cancer immunology research

P1476

Resistance to Antiangiogenic T ...... tastatic Renal Cell Carcinoma.

@en

P2093

Alper Yetil

http://www.w3.org/2001/XMLSchema#string

Amado Zurita

http://www.w3.org/2001/XMLSchema#string

Anh Hoang

http://www.w3.org/2001/XMLSchema#string

Arjan W Griffioen

http://www.w3.org/2001/XMLSchema#string

Axel Bex

http://www.w3.org/2001/XMLSchema#string

Christopher Wood

http://www.w3.org/2001/XMLSchema#string

Eric Jonasch

http://www.w3.org/2001/XMLSchema#string

Jianjun Gao

http://www.w3.org/2001/XMLSchema#string

Jose A Karam

http://www.w3.org/2001/XMLSchema#string

Kanishka Sircar

http://www.w3.org/2001/XMLSchema#string

P2860

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes

The blockade of immune checkpoints in cancer immunotherapy

Myeloid-derived suppressor cells as regulators of the immune system

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

How regulatory T cells work

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

P304

1017-1029

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-14-0244

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273122903

http://www.w3.org/2001/XMLSchema#string

P698

26014097

http://www.w3.org/2001/XMLSchema#string

P932

4561186

http://www.w3.org/2001/XMLSchema#string